Imlifidase is a drug designed to enable kidney transplantation for highly sensitized patients. The treatment is conditionally approved in the EU and the UK under the name Idefirix.
Results have now been presented from a U.S. Phase III study evaluating 12-month kidney function in highly sensitized adult kidney transplant patients with positive crossmatch against a deceased donor, compared to a control arm.
BREAKING